Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Generic Labeling Rule Could Help Pfizer In Reglan Product Liability Suit

This article was originally published in The Pink Sheet Daily

Executive Summary

Alabama Supreme Court is reconsidering its decision holding brand-name manufacturers liable for injuries caused by generics; Pfizer argues that FDA’s forthcoming proposed rule would eliminate concerns that no company could be held liable for injuries from a generic.

You may also be interested in...



Pfizer Litigation Strategy: Business Focus, Legal Alliance Drive Successes

Pfizer’s litigation department scored several key victories in the past year, which the company chalks up to its business approach to running cases and the teamwork of its law firms.

Rx Injury Claims May Grow After Court Finds Brand Liable For Generic Problems

The pharmaceutical industry is reeling from a court ruling that found brand name manufacturers are liable for the warnings on generic versions of their products

Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics

FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel